Welcome to the e-CCO Library!

OP017: Transanal minimally invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with ulcerative colitis: a cohort study from the TaTME international database
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Pellino1,2*, K. Sahnan2,3, M. Penna3,4, S. Adegbola2,3, P. Chandrasinghe2,3,5, A. Spinelli6,7, R. Hompes4, J. Warusavitarne2,3, on behalf of the International TaTME Registry Collaborative.

Created: Thursday, 21 February 2019, 9:14 AM
OP018: High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Mascaraque1, S. Elangovan2, L. Petti1, A. Piontini2, C. Correale1, V. Arena3, B. Romano1, F. Ungaro2, V. Garlatti2, S. D’Alessio2, G. Fiorino1, A. Spinelli2,4, S. Danese1,2, S. Vetrano2*

Created: Thursday, 21 February 2019, 9:14 AM
OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling
Year: 2018
Source: ECCO'18 Vienna
Authors: Elangovan Sudharshan
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kanis S.
Last Modified: Wednesday, 15 March 2017, 2:22 PM by Vesna Babaja
Anti TNF drug levels, Anti TNF agents, IBD in pregnancy
Files: 1
OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kanis S., de Lima A., van der Woude C.

Created: Wednesday, 20 February 2019, 10:36 AM
OP018: The impact of Crohns Disease-TReatment-with-EATing diet (CD-TREAT diet) and exclusive enteral nutrition on healthy gut bacteria metabolism
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

V. Svolos*1, R. Hansen2, K. Hughes1, U. Z. Ijaz3, C. Quince4, D. Gaya5, R. Russell2, K. Gerasimidis1

Created: Friday, 22 February 2019, 9:49 AM
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Feagan B.*1, Colombel J.-F.2, Rossiter G.3, Li X.3, Usiskin K.3, Zhan X.3, Sands B.2

Created: Wednesday, 20 February 2019, 10:36 AM
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn’s Disease treated with mongersen (GED- 0301)
Year: 2017
Source: ECCO'17 Barcelona
Authors: Feagan B.
Last Modified: Wednesday, 15 March 2017, 2:34 PM by ECCO Administrator
Mongersen
Files: 1
OP019: Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

W. J. Sandborn1, B. E. Sands2, G. D’Haens*3, S. Vermeire4, S. Schreiber5, S. Danese6, J. Panés7, B. G. Feagan8, W. Reinisch9, W. Niezychowski10, G. Friedman10, N. Lawendy10, D. Yu10, D. Woodworth10, A. Mukherjee11, P. Healey11, H. Zhang10, C. Su10

Created: Friday, 22 February 2019, 9:49 AM
OP019: In faecal microbiota transplantation (FMT) for ulcerative colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short-chain fatty acid production are associated with remission (FOCUS study)
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Paramsothy1,2*, M. Kamm3,4, S. Nielsen1, N. Deshpande1, J. Faith2, J. Clemente2, R. Paramsothy5, A. Walsh6, J. van den Bogaerde7, D. Samuel8, R. Leong8, S. Connor5, W. Ng5, E. Lin9, M. Wilkins1, J.-F. Colombel2, T. Borody9, H. Mitchell1, N. Kaakoush1

Created: Thursday, 21 February 2019, 9:14 AM
OP01: Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Levine, A.(1,2);Scaldaferri, F.(3,4);Sarbagili Shabat, C.(1,2);Zittan, E.(5);Hirsch, A.(2,6);Mentella, M.C.(7);Musca , T.(7);Cohen, N.A.(6);Ron, Y.(6);Fliss Isakov , N.(6);Pfeffer, J.(6);Yaakov, M.(1);Fanali, C.(4);Turchini , L.(4);Masucci, L.(8,9);Quaranta, G.(8,9);Anastasia, G.(10);Weinberger, A.(10);Kopylov , U.(2,11);Maharshak, N.(2,6)
Created: Wednesday, 2 June 2021, 4:12 PM
OP01: Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Arie Levine
Created: Friday, 1 October 2021, 12:41 PM
Background

We evaluated if integration of novel diets for donors and patients in addition to fecal transplantation (FT) could increase FT remission in refractory ulcerative colitis (UC) or have an independent effect on remission. We developed a novel diet specifically designed for the dysbiosis of UC and to decrease factors that impair goblet cells or mucous production.

Methods

This was a blinded randomized controlled pilot trial in adults with UC, defined by a simple clinical colitis activity index (SCCAI) of ≥5 and < 11 and endoscopic Mayo score 2-3, refractory to medication. Group 1 received free diet and standard FT by colonoscopy on day 1and rectal enemas from a single donor on days 2 and 14 without dietary conditioning of the donor. Group 2: FT as above but with dietary pre-conditioning of the donor for 14 days and a diet (UC Diet- UCD) for the patients after FT. Group 3 received the UC Diet alone without FT. Patients underwent a repeat endoscopy at week 8. The primary endpoint was clinical steroid free remission, defined as SCCAI <3, at week 8.

Results

Fifty-one of the 96 planned patients were enrolled. The mean age was 40.4 ±12.5 years, 28/51(54.9%) had failed a biologic, 15/40 (29.4%) were on steroids at enrolment.  Remission week 8 in Group 1 was 2/17(11.8%), Group 2 was 4/19 (21.1%), and 6/15 (40%) Group 3 (NS).  Endoscopic remission was present in Group 1: 2/17(12%), Group 2: 3/19(16%) and 4/15 (27%) Group 3. Mucosal healing (Mayo 0) was achieved only in Group 3 (3/15, 20%) vs. 0/36 patients receiving FT (P=0.022). Exacerbation of disease occurred in 3/17 (17.6%) Group1, 4/19 (21.1%) Group 2, and 1/15 (6.7%) Group 3 (NS). The study was stopped for futility by a safety monitoring board.

Conclusion

Fecal transplantation was not effective in this UC cohort. A UC Diet alone appeared to achieve higher clinical remission (40%) and mucosal healing than single donor FT with or without diet in mild to moderate UC failing medical therapy. This diet should be investigated further in a RCT specifically designed for the UCD. This study was supported by an ECCO Pioneer grant

OP01: In-depth characterisation of host genetics and gut microbiome unravels novel host–microbiome interactions in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Hu*1, A. Vich Vila1, R. Gacesa1, V. Collij1, R. Xavier2, C. Stevens3, M. Daly3, C. Wijmenga4, H. van Dullemen1, G. Dijkstra1, M. Visschedijk1, E. Festen1, J. Fu5, A. Kurilshikov4, A. Zhernakova4, R. Weersma1

Created: Friday, 22 February 2019, 9:41 AM
OP01: In-depth characterization of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel Disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Shixian Hu
Created: Tuesday, 28 May 2019, 3:32 PM
Genetic factors, Microbiota, Crohn’s disease, Ulcerative colitis, Genetics, Microbiota
Files: 1
OP01: Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Verstockt, S.(1)*;Machiels, K.(1);Dehairs, J.(2);Rems, K.(1);De Greef, I.(1);Jans, D.(3);Sabino, J.(1,4);Ferrante, M.(1,4);Vermeire, S.(1,4);Verstockt, B.(1,4);
Created: Friday, 14 July 2023, 10:43 AM